Serum PIIINP >5.0 µg/L at day 4 after acute MI was associated with lack of LV ejection fraction improvement at 360 days (43% vs 54% in patients with PIIINP ≤5.0 µg/L) and predicted adverse outcomes.
Cohort (n=63)
Absolute Event Rate: 43% vs 54%
BACKGROUND: The amino-terminal propeptide of type III procollagen (PIIINP) is a marker of type III collagen synthesis, which has previously been shown to correlate with infarct size in nonthrombolyzed myocardial infarction (MI) and to provide prognostic information after MI. METHODS AND RESULTS: The relationship between PIIINP and changes of left ventricular (LV) function was studied in 47 consecutive patients with first acute MI and 16 control subjects. Serum PIIINP analysis was measured daily during hospitalization and on days 90, 180, and 360. LV function was assessed by echocardiography on days 1, 5, 90, and 360. Patients with MI were stratified according to their serum PIIINP value at day 4 (group A, 5.0 microg/L). On arrival, LV function and size were comparable between groups A (n=31) and B (n=16). LV ejection fraction, initially depressed (day 1: group A, 47+/-7% versus group B, 47+/-8%; P=NS), increased significantly in group A (day 360: 54+/-8%, P5.0 microg/L and deceleration </=140 ms as independent predictors of cardiac death or complicating heart failure during follow-up. CONCLUSIONS: PIIINP assessed in the subacute phase of MI relates to long-term changes of LV function and provides clinical prognostic information.
Poulsen et al. (Tue,) conducted a cohort in Acute Myocardial Infarction (n=63). Serum PIIINP >5.0 microg/L at day 4 vs. Serum PIIINP ≤5.0 microg/L at day 4 was evaluated on Left ventricular ejection fraction at day 360. Serum PIIINP >5.0 µg/L at day 4 after acute MI was associated with lack of LV ejection fraction improvement at 360 days (43% vs 54% in patients with PIIINP ≤5.0 µg/L) and predicted adverse outcomes.